UniDoc Health Corp Launches $100,000 Non-Brokered Private Placement of Convertible Debentures

Details of Convertible Debenture Terms and Structure

UniDoc's unsecured convertible debentures will mature two years after issuance and pay 6.0% interest annually. The company holds the right to prepay all or part of the debentures in cash before maturity, offering flexibility in debt management. These debentures are offered on a non-brokered basis, meaning they will be placed directly with investors rather than through intermediaries.

The debentures are non-transferable, restricting secondary market trading and limiting investors’ ability to resell. This is typical for private placements designed to maintain a controlled investor base. All securities issued under this offering, including those from conversion, will be subject to a four-month statutory hold period per Canadian securities laws, preventing immediate resale.

Conversion Features and Future Financing Event Triggers

A key aspect of the debentures is their conditional conversion feature, which activates upon a "Future Financing Event." This event occurs when UniDoc completes subsequent issuances of securities via private placement or public offering, including common shares, unit subscription receipts, special warrants, or convertible debt. Upon such an event, the company may choose to repay the debentures by converting them into units instead of cash.

Each converted unit will comprise one common share and one common share purchase warrant. The conversion price per unit will match the price per security issued in the selected Future Financing Event, subject to a minimum price requirement under Canadian Securities Exchange policies. This structure enables UniDoc to align debenture repayment with future capital-raising activities, enhancing capital structure flexibility.

Warrant Terms and Exercise Conditions

Warrants issued upon conversion will mirror the terms of those issued in the chosen Future Financing Event. If that event includes units with shares and warrants, the conversion warrants will have identical exercise prices and expiry dates, ensuring consistency for investors.

If the Future Financing Event does not include standalone warrants, the conversion warrants will have a three-year term from issuance, with an exercise price set at the market price of UniDoc’s common shares at the announcement of the financing. This dual-path approach provides clear exercise terms regardless of the financing structure.

Allocation of Proceeds and Corporate Use

UniDoc intends to use the proceeds primarily for working capital and general corporate purposes, though specific allocations were not detailed. Working capital typically covers short-term operational expenses such as inventory and payroll, while general corporate purposes may include administrative costs and strategic initiatives.

The relatively small size of the $100,000 offering indicates a focus on supporting near-term operational needs rather than large-scale expansion or acquisitions. Investors may require additional disclosures or direct engagement with management to understand precise fund allocation.

Regulatory Approvals and Closing Conditions

The completion of the private placement depends on obtaining all required corporate and regulatory approvals, including from the Canadian Securities Exchange. No timeline for closing or regulatory review was provided. As a CSE-listed entity, UniDoc must comply with exchange requirements before finalizing the offering.

The announcement includes forward-looking statements about the offering’s completion, proceeds, intended use, and regulatory approvals, noting that actual outcomes may differ due to risks and uncertainties. Investors should be aware of the risks related to completion and regulatory uncertainties.

Company Overview and Business Model

UniDoc Health Corp is developing an eHealth platform designed as a self-contained remote virtual clinic housed within a private kiosk. This solution aims to enable patients to conduct full consultations as if physically present in a physician’s office. The company emphasizes physical accessibility as a key advantage in overcoming barriers related to access, experience, or familiarity with online technology.

UniDoc trades on the CSE under ticker UDOC, on the Frankfurt exchange as FRA: L7T, and on OTCQB as UDOCF. The company’s strategic goal is to unlock shareholder value by delivering a superior product and building a robust commercial network rapidly. More information is available at www.unidoctor.com, where updates on corporate activities can be subscribed to.

Market Position and Capital Strategy

This convertible debenture offering reflects UniDoc’s strategy to raise growth capital while maintaining capital structure flexibility. Conversion rights linked to future financing events indicate expectations of additional capital raises ahead. This structure allows deferral of dilution while ensuring debenture holders participate proportionally in future financings.

The non-brokered nature suggests targeting select investors familiar with UniDoc, reducing distribution costs and streamlining regulatory approvals. Existing shareholders should note that conversion may lead to future dilution depending on financing events and management’s conversion decisions.

Forward-Looking Statements and Risk Factors

UniDoc’s announcement contains forward-looking information regarding offering completion, debenture terms, prepayment and conversion rights, future financing events, and regulatory approvals. These statements reflect management’s current views and estimates and may differ materially from actual results.

Risks include regulatory approval delays, market conditions affecting financing access, securities valuation changes impacting conversion, and operational challenges. The company will update forward-looking statements only as required by law. Investors should review full disclosures on the CSE website for detailed risk information.

Investor Guidance on the Offering

Prospective investors should consider UniDoc’s modest $100,000 capital raise aimed at near-term operational support rather than major growth. The conversion features add complexity, as the securities ultimately received depend on management’s future financing choices and pricing.

The four-month hold period restricts immediate liquidity post-conversion. Additionally, the company’s discretion in selecting the Future Financing Event for conversion pricing may affect warrant valuation and stock price. Investors are advised to thoroughly review terms, understand conversion mechanics, and assess UniDoc’s track record in executing its eHealth strategy and capital market access.